Related Experiment Video

Updated: Apr 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

Katy K Tsai1, Adil I Daud

  • 1Division of Hematology/Oncology, Department of Medicine, University of California San Francisco (UCSF), Mount Zion A-743, 1600 Divisadero Street, San Francisco, CA, 94143, USA.

Drugs
|March 25, 2015
PubMed

Insights

Immune checkpoint inhibitors, like anti-programmed death 1 (PD-1) therapies, are revolutionizing cancer treatment. Blocking the PD-1/PD-L1 interaction shows significant anti-cancer activity, especially in melanoma.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoints regulate immune responses.
  • Cancer cells exploit immune checkpoints to evade immune surveillance.
  • Programmed death 1 (PD-1) is a key inhibitory checkpoint molecule.

Purpose of the Study:

  • To review the role of the PD-1 pathway in cancer immune evasion.
  • To discuss the anti-cancer mechanisms of PD-1/PD-L1 blockade.
  • To summarize efficacy and safety data of PD-1 inhibitors.

Main Methods:

  • Literature review of PD-1 pathway research.
  • Analysis of clinical trial data for PD-1 inhibitors.
  • Discussion of current and future therapeutic strategies.

Main Results:

  • PD-1/PD-L1 blockade demonstrates significant anti-cancer activity.
  • Two anti-PD-1 drugs received accelerated approval for metastatic melanoma.
  • Immunotherapy is a validated treatment modality for melanoma.

Conclusions:

  • PD-1 pathway inhibition is a promising cancer therapy.
  • Further research is needed to optimize patient outcomes.
  • PD-1 blockade may be applicable to other cancer types.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K